Bioactive Conformation I
Published on 18. November 2010
Book
Paperback/Softback
XII, 309 pages
978-3-642-08035-7 (ISBN)
Description
This series presents critical reviews of the present position and future trends in modern chemical research. It contains short and concise reports on chemistry, each written by the world renowned experts -- it is still valid and useful after 5 or 10 years. More information as well as the electronic version of the whole content available at: springerlink.com. The book will appeal to scientists and practitioners in the mentioned fields and in industry.
Reviews / Votes
From the reviews:
"Bioactive Conformation I contains eight chapters on quite different topics within the theme of the series. . it will be essential reading for any researcher working in any area that involves binding of a substance to a protein." (T. B. Grindley, Journal of the American Chemical Society, Vol. 130 (2), 2008)
More details
Series
Edition
1st ed. Softcover of orig. ed. 2007
Language
English
Place of publication
Berlin
Germany
Publishing group
Springer Berlin
Target group
Professional and scholarly
Professional/practitioner
Illustrations
XII, 309 p.
Dimensions
Height: 235 mm
Width: 155 mm
Thickness: 18 mm
Weight
493 gr
ISBN-13
978-3-642-08035-7 (9783642080357)
DOI
10.1007/978-3-540-49078-4
Schweitzer Classification
Other editions
Additional editions
Content
Spatial Screening for the Identification of the Bioactive Conformation of Integrin Ligands.- Dynamics and Thermodynamics of Ligand-Protein Interactions.- The Fibroblast Growth Factor (FGF) - FGF Receptor Complex: Progress Towards the Physiological State.- Characterization of Interactions Between Misfolding Proteins and Molecular Chaperones by NMR Spectroscopy.- NMR Analysis of Bioprotective Sugars: Sucrose and Oligomeric (1?2)-?-D-glucopyranosyl-(1?2)-?-D-fructofuranosides.- Residual Dipolar Couplings Report on the Active Conformation of Rhodopsin-Bound Protein Fragments.- Glycosyltransferase Structure and Function.- Exploiting Ligand and Receptor Adaptability in Rational Drug Design Using Dynamics and Structure-Based Strategies.